Evidence map›Paper›PMID 26781748›Full record

ArticleBMC genomics2016

Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs.

Mark Wappett, Austin Dulak, Zheng Rong Yang, Abdullatif Al-Watban, James R Bradford, Jonathan R Dry

Abstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Overcoming selection bias in synthetic lethality prediction.Bioinformatics (Oxford, England) · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Synthetic lethality and cancer.Nature reviews. Genetics · 2017
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mark WappettOncology Innovative Medicines, AstraZeneca, Macclesfield, UK. mark.wappett@almacgroup.com.
Austin DulakOncology Innovative Medicines, AstraZeneca, Waltham, USA. austin.dulak@astrazeneca.com.
Zheng Rong YangSchool of Biosciences, University of Exeter, Exeter, UK. Z.R.Yang@exeter.ac.uk.
Abdullatif Al-WatbanSchool of Biosciences, University of Exeter, Exeter, UK. asa220@exeter.ac.uk.
James R BradfordOncology Innovative Medicines, AstraZeneca, Macclesfield, UK. j.r.bradford@sheffield.ac.uk.
Jonathan R DryOncology Innovative Medicines, AstraZeneca, Waltham, USA. Jonathan.Dry@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentification of synthetic lethal interactions in cancer cells could offer promising new therapeutic targets. Large-scale functional genomic screening presents an opportunity to test large numbers of cancer synthetic lethal hypotheses. Methods enriching for candidate synthetic lethal targets in molecularly defined cancer cell lines can steer effective design of screening efforts. Loss of one partner of a synthetic lethal gene pair creates a dependency on the other, thus synthetic lethal gene pairs should never show simultaneous loss-of-function. We have developed a computational approach to mine large multi-omic cancer data sets and identify gene pairs with mutually exclusive loss-of-function. Since loss-of-function may not always be genetic, we look for deleterious mutations, gene deletion and/or loss of mRNA expression by bimodality defined with a novel algorithm BiSEp.

resultsApplying this toolkit to both tumour cell line and patient data, we achieve statistically significant enrichment for experimentally validated tumour suppressor genes and synthetic lethal gene pairings. Notably non-reliance on genetic loss reveals a number of known synthetic lethal relationships otherwise missed, resulting in marked improvement over genetic-only predictions. We go on to establish biological rationale surrounding a number of novel candidate synthetic lethal gene pairs with demonstrated dependencies in published cancer cell line shRNA screens.

conclusionsThis work introduces a multi-omic approach to define gene loss-of-function, and enrich for candidate synthetic lethal gene pairs in cell lines testable through functional screens. In doing so, we offer an additional resource to generate new cancer drug target and combination hypotheses. Algorithms discussed are freely available in the BiSEp CRAN package at http://cran.r-project.org/web/packages/BiSEp/index.html .

Indexed as

Genes, LethalGenes, SyntheticProteomicsComputational BiologyGenomicsHumansMutationNeoplasms

Identifiers

PMID26781748
PMCPMC4717622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.